Viiv Healthcare Mpp Sign New Voluntary Licensing Agreement To Expand Access To Innovative Long Acting Hiv Prevention Medicine

Viiv Healthcare, The Global Specialist Hiv Company Majority Owned By Gsk, With Pfizer And Shionogi As Shareholders, And The Medicines Patent Pool (Mpp), Announced The Signing Of A New Voluntary Licensing Agreement For Patents Relating To Cabotegravir Long-Acting (La) For Hiv Pre-Exposure Prophylaxis (Prep) To Help Enable Access In Least Developed, Low-Income, Lower Middle-Income And Sub-Saharan African Countries.Through This Agreement, Selected Generic Manufacturers Will Have The Opportunity To Develop, Manufacture And Supply Generic Versions Of Cabotegravir La For Prep, The First Long-Acting Hiv Prevention Medicine, In 90 Countries, Subject To Required Regulatory Approvals Being Obtained. It Is Expected That This Agreement Will Help To Enable At-Scale Access To Generic Cabotegravir La For Prep. This Announcement Comes Just Seven Months After The First Regulatory Approval Of Cabotegravir La For Prep In The World, By The Us Food And Drug Administration (Fda).Each Year, There Are Approximately 1.5 Million New Cases Of Hiv Worldwide, Most Of Which Occur In Resource-Limited Countries, With Women And Adolescent Girls Disproportionately Impacted. While Oral Prep Options Are Available In Many Countries, Challenges With Adherence And Stigma Have Limited Their Impact In Some Populations. Access To An Effective Long-Acting Hiv Prevention Option Could Significantly Contribute Towards The Goal Of Ending The Epidemic. The New Voluntary Licence Announced Today Builds On A Long-Standing Partnership Between Viiv Healthcare And Mpp, Which Has Been Highly Successful In Facilitating The Manufacture And Sale Of Generic Versions Of Oral Viiv Healthcare Medicines In Countries Most Affected By Hiv And Least Able To Pay For Treatment And Care. In Particular, Voluntary Licensing Has Enabled Access To Generic Products Containing Another Of Viiv Healthcare

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!